{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T05:14:34Z","timestamp":1733462074711,"version":"3.30.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"DOI":"10.7759\/cureus.75155","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T15:07:54Z","timestamp":1733411274000},"source":"Crossref","is-referenced-by-count":0,"title":["Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis"],"prefix":"10.7759","author":[{"given":"Steven Y","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda  E","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillis","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi A","year":"2014","unstructured":"Tefferi A, Lasho TL, Tischer A, et al.. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014, 124:2465-6. 10.1182\/blood-2014-07-588426","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta J","year":"2014","unstructured":"Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014, 55:595-600. 10.3109\/10428194.2013.813500","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.11.004","article-title":"The role of megakaryocytes in myelofibrosis","volume":"35","author":"Melo-Cardenas J","year":"2021","unstructured":"Melo-Cardenas J, Migliaccio AR, Crispino JD. The role of megakaryocytes in myelofibrosis. Hematol Oncol Clin North Am. 2021, 35:191-203. 10.1016\/j.hoc.2020.11.004","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00470-y","article-title":"Mutations and thrombosis in essential thrombocythemia","volume":"11","author":"Guglielmelli P","year":"2021","unstructured":"Guglielmelli P, Gangat N, Coltro G, et al.. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J. 2021, 11:77. 10.1038\/s41408-021-00470-y","journal-title":"Blood Cancer J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi A","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, et al.. GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018, 32:1631-42. 10.1038\/s41375-018-0107-z","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.09.001","article-title":"Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns","volume":"37","author":"Barcellini W","year":"2013","unstructured":"Barcellini W, Iurlo A, Radice T, et al.. Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk Res. 2013, 37:1509-15. 10.1016\/j.leukres.2013.09.001","journal-title":"Leuk Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n A","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Guglielmelli P, et al.. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016, 101:926-31. 10.3324\/haematol.2016.146654","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24788","article-title":"Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease","volume":"92","author":"Jeryczynski G","year":"2017","unstructured":"Jeryczynski G, Thiele J, Gisslinger B, et al.. Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017, 92:885-91. 10.1002\/ajh.24788","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: Treatment algorithm 2018","volume":"8","author":"Finazzi G","year":"2018","unstructured":"Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: Treatment algorithm 2018. Blood Cancer J. 2018, 8:104. 10.1038\/s41408-018-0142-z","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky RA","year":"2019","unstructured":"Brodsky RA. Warm autoimmune hemolytic anemia. N Engl J Med. 2019, 381:647-54. 10.1056\/NEJMcp1900554","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003808","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini W","year":"2021","unstructured":"Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia. Blood. 2021, 137:1283-94. 10.1182\/blood.2019003808","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0578-9","article-title":"Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity","volume":"91","author":"Barcellini W","year":"2010","unstructured":"Barcellini W, Revelli N, Imperiali FG, et al.. Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity. Int J Hematol. 2010, 91:762-9. 10.1007\/s12185-010-0578-9","journal-title":"Int J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309378-warm-autoimmune-hemolytic-anemia-as-a-rare-presentation-of-pre-fibrotic-primary-myelofibrosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T15:07:55Z","timestamp":1733411275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309378-warm-autoimmune-hemolytic-anemia-as-a-rare-presentation-of-pre-fibrotic-primary-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.75155","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}